Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”
Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”. // Pharmacoepidemiology and Drug Safety. – 2026. – DOI: 10.1002/pds.70522. – URL: https://onlinelibrary.wiley.com/doi/10.1002/pds.70522?af=R
(2026). Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70522
“Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”.” Pharmacoepidemiology and Drug Safety, 2026. doi:10.1002/pds.70522.
@article{article85500,
title = {Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70522},
url = {https://onlinelibrary.wiley.com/doi/10.1002/pds.70522?af=R}
}